
-
Galera Therapeutics OTC Markets OTCPK:GRTX Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy that is in Phase 2a clinical trial. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Location: 101 Lindenwood Drive, Malvern, PA, 19355, United States | Website: https://www.galeratx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
149M
Cash
6.686M
Avg Qtr Burn
-2.398M
Short % of Float
4.81%
Insider Ownership
32.84%
Institutional Own.
9.99%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tilarginine + paclitaxel Details Cancer, Triple Negative Breast Cancer | Phase 2 Initiation | |
Tilarginine + nab-paclitaxel + alpelisib Details Cancer, Metastatic Breast Cancer | Phase 1/2 Data readout | |
Avasopasem + (fulvestrant +CDK4/6i) Details Cancer, HR+/HER2-Metastatic Breast Cancer | Phase 1/2 Initiation | |
Rucosopasem Details Cancer, Non-small cell lung carcinoma | Failed Discontinued | |
Rucosopasem Details Pancreatic cancer, Cancer | Failed Discontinued | |
Avasopasem Manganese (GC4419) Details Lung cancer, Esophagitis, Non-small cell lung carcinoma | Failed Discontinued | |
Avasopasem Manganese (GC4419) Details Infectious disease, COVID-19 | Failed Discontinued | |
Avasopasem Manganese (GC4419) Details Head and neck cancer, Cancer | Failed Discontinued |